Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of the Medical Sciences
- Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis. 2007; 44: S27-S72
- Compliance with severe sepsis bundles and its effect on patient outcomes of severe community-acquired pneumonia in a limited resources country.Arch Med Sci. 2014; 10: 970-978
- Evaluation of the IDSA/ATS minor criteria for severe community-acquired pneumonia.Hosp Pract (1995). 2012; 40: 158-164
- Weight of the IDSA/ATS minor criteria for severe community-acquired pneumonia.Respir Med. 2011; 105: 1543-1549
- Mortality among severe community-acquired pneumonia patients depends on combinations of 2007 IDSA/ATS minor criteria.Int J Infect Dis. 2015; 38: 141-145
- Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.Crit Care Med. 2009; 37: 3010-3016
- Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission.Clin Infect Dis. 2009; 48: 377-385
- Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia.Thorax. 2009; 64: 598-603
- Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.Am J Respir Crit Care Med. 2001; 163: 1730-1754
- Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.Crit Care Med. 2004; 32: 858-873
- Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.Crit Care Med. 2008; 36: 296-327
- Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis.Thorax. 2010; 65: 878-883
Funding: This study was funded by the medical science and technology foundation of Guangdong province in 2010 (No. A2010553), the planned science and technology project of Shenzhen municipality in 2011 (No. 201102078) and the nonprofit scientific research project of Futian district in 2011 (No. FTWS201120).
Disclosures: All authors report no conflict of interest.
ScienceDirectAccess this article on ScienceDirect
- Notice of Overlapping Publication: Priority for Treatment and Intensive Care of Patients With Nonsevere Community-Acquired Pneumonia [Li et al. Am J Med Sci, 2018; 356(4):329]The American Journal of the Medical SciencesVol. 358Issue 2
- PreviewThe Editorial Office wishes to disclose overlapping publications. In the October 2018 issue of The American Journal of the Medical Sciences, we published “Priority for Treatment and Intensive Care of Patients With Non-Severe Community-Acquired Pneumonia” by Li et al. The database used in this manuscript overlapped or partly overlapped with databases used in other published articles including Li et al. Am J Med Sci, 2015, 350(3): 186; Li et al. Medicine, 2015, 94(36):e1474; Guo et al. Respir Res, 2019, 20(1):22; and Guo et al.
- Putting the CAP on ICU Admissions: Can Clinical Prediction Tools Help Determine Appropriate Site of Care?The American Journal of the Medical SciencesVol. 356Issue 4
- PreviewCommunity-acquired pneumonia (CAP) is the most common cause of infectious disease related mortality and a major burden to hospital and intensive care unit (ICU) resources.1 Clinical prediction rules such as the Pneumonia Severity Index (PSI) and CURB-65 have been developed to assess severity of illness to help determine the appropriate site of treatment and potentially avoid overutilization of these finite resources.2 Patients with PSI Class IV-V and CURB-65 scores 2-5 have a predicted mortality of 8.2% and 9.2%, respectively.